EICHORCondition: Myelodysplastic Syndrome · MDS · Refractory Anemia With Excess Blasts · Sponsor: Traws Pharma, Inc.
The study's primary objective \[in a population of patients with MDS after failure of treatment with azacitidine (AZA) or decitabine (DAC)\], is to compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk.
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| UC San Diego Moores Cancer Center | La Jolla, California, United States | — |
| USC Norris Comprehensive Cancer Center | Los Angeles, California, United States | — |
| UCLA Medical Center | Los Angeles, California, United States | — |
| Cancer Specialists of North Florida | Fleming Island, Florida, United States | — |
| UF Health Shands Cancer Hospital | Gainesville, Florida, United States | — |
| Mid Florida Hematology and Oncology Centers | Orange City, Florida, United States | — |
| Advanced Research Institute, Inc | St. Petersburg, Florida, United States | — |
| Rush University Medical Center | Chicago, Illinois, United States | — |
| University of Illinois Cancer Center | Chicago, Illinois, United States | — |
| Loyola University Chicago at Loyola University Medical Center | Maywood, Illinois, United States | — |
| Indiana University Health Hospital | Indianapolis, Indiana, United States | — |
| The University of Kansas Cancer Center | Westwood, Kansas, United States | — |
+ 146 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02562443